...
首页> 外文期刊>Clinical and diagnostic laboratory immunology >Plasma-Soluble CD30 in Childhood Tuberculosis: Effects of Disease Severity, Nutritional Status, and Vitamin A Therapy
【24h】

Plasma-Soluble CD30 in Childhood Tuberculosis: Effects of Disease Severity, Nutritional Status, and Vitamin A Therapy

机译:儿童结核病中的血浆可溶性CD30:疾病严重程度,营养状况和维生素A治疗的影响

获取原文
           

摘要

Plasma-soluble CD30 (sCD30) is the result of proteolytic splicing from the membrane-bound form of CD30, a putative marker of type 2 cytokine-producing cells. We measured sCD30 levels in children with tuberculosis, a disease characterized by prominent type 1 lymphocyte cytokine responses. We postulated that disease severity and nutritional status would alter cytokine responses and therefore sCD30 levels. Samples from South African children enrolled prospectively at the time of diagnosis of tuberculosis were analyzed. (Patients were originally enrolled in a randomized, double-blind placebo-controlled study of the effects of oral vitamin A supplementation on prognosis of tuberculosis.) Plasma samples collected at the time of diagnosis and 6 and 12 weeks later (during antituberculosis therapy) were analyzed. sCD30 levels were measured by enzyme immunoassay. The 91 children included in the study demonstrated high levels of sCD30 at diagnosis (median, 98 U/liter; range, 11 to 1,569 U/liter). Although there was a trend toward higher sCD30 levels in more severe disease (e.g., culture-positive disease or miliary disease), this was not statistically significant. Significantly higher sCD30 levels were demonstrated in the presence of nutritional compromise: the sCD30 level was higher in patients with a weight below the third percentile for age, in those with clinical signs of kwashiorkor, and in those with a low hemoglobin content. There was minimal change in the sCD30 level after 12 weeks of therapy, even though patients improved clinically. However, changes in sCD30 after 12 weeks differed significantly when 46 patients (51%) who received vitamin A were compared with those who had received a placebo. Vitamin A-supplemented children demonstrated a mean (± standard error of the mean) decrease in sCD30 by a factor of 0.99 ± 0.02 over 12 weeks, whereas a factor increase of 1.05 ± 0.02 was demonstrated in the placebo group (P = 0.02). We conclude that children with tuberculosis had high sCD30 levels, which may reflect the presence of a type 2 cytokine response. Nutritional compromise was associated with higher sCD30 levels. Vitamin A therapy resulted in modulation of sCD30 levels over time.
机译:血浆可溶性CD30(sCD30)是CD30膜结合形式的蛋白水解剪接的结果,CD30是2型细胞因子产生细胞的一种可能的标志物。我们测量了结核病患儿的sCD30水平,该病的特征是突出的1型淋巴细胞细胞因子应答。我们推测疾病的严重程度和营养状况会改变细胞因子的反应,从而改变sCD30的水平。分析了在诊断结核病时前瞻性招募的南非儿童的样本。 (患者最初参加了口服维生素A补充剂对结核病预后影响的随机,双盲安慰剂对照研究。)在诊断时以及治疗后6周和12周(在抗结核治疗期间)收集血浆样品。分析。 sCD30水平通过酶免疫测定法测量。纳入研究的91名儿童在诊断时显示出高水平的sCD30(中位数为98 U /升;范围为11至1,569 U /升)。尽管在更严重的疾病(例如培养阳性或粟粒性疾病)中存在sCD30水平升高的趋势,但这在统计学上并不显着。在营养受损的情况下,sCD30水平显着升高:年龄在体重第三位以下的患者,具有kwashiorkor临床症状的患者和血红蛋白含量低的患者,sCD30水平较高。治疗12周后,即使患者的临床状况有所改善,sCD30水平的变化却很小。但是,当将46位接受维生素A的患者(51%)与接受安慰剂的患者进行比较时,十二周后sCD30的变化有显着差异。补充维生素A的儿童在12周内显示sCD30的平均值(平均值的标准误)降低0.99±0.02,而安慰剂组则提高了1.05±0.02( P < / em> = 0.02)。我们得出结论,患有结核病的儿童的sCD30水平较高,这可能反映了2型细胞因子反应的存在。营养受损与较高的sCD30水平有关。维生素A治疗可导致sCD30水平随时间而调节。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号